June 30, 2020

EuropaBio observations in response to Europe’s Beating Cancer Plan

EuropaBio welcomes the European Commission’s commitment to develop a European plan to fight cancer and is supportive of its overarching approach in tackling all key stages of the disease: prevention, early diagnosis, treatment, and quality of life. Above all, we strongly advocate the employment of supportive measures for health innovation to ensure that novel cancer treatments move from the laboratory to the hospital bedside as swiftly as possible.
June 22, 2020

EuropaBio position on the EU Biodiversity Strategy for 2030

Read our position on the EU 2030 Biodiversity Strategy.
June 19, 2020

ACCELERATE FAIR Initiative Letter of Support

We do appreciate the efforts led by the FAIR Initiative and hope to continue to partner with ACCELERATE to speed up the delivery of innovative therapies to children and adolescents.
June 17, 2020

EU-UK Future Relations – Joint Letter Life Sciences Coalition

The pharmaceutical and biotechnology industries are doing everything in their power to prepare for all scenarios and need the support of the European Union to ensure that we can fulfil our promise to the patients who we serve.
May 20, 2020

EuropaBio position on Germline Genome Editing

EuropaBio and its members strongly believe that genome editing will enable the development of many solutions to the grand challenges facing both people and planet. In medicine, genome editing offers the prospect of saving lives and tackling some of the most devastating genetic diseases.
April 29, 2020

European Bioeconomy Alliance (EUBA) Position on the EU Green Deal

The European Bioeconomy Alliance (EUBA), of which EuropaBio is a founding member, today published its position on the EU Green Deal.
April 10, 2020

European Industry trade and supply chain needs to respond to Covid-19 – Joint Letter to the EU Trade Ministers

European Industry trade and supply chain needs to respond to Covid-19 - Joint Letter to the EU Trade Ministers.
March 9, 2020

EuropaBio Position & Policy Recommendations to support EU ATMP Innovation

To ensure the EU remains a leader in ATMP innovation, this paper outlines and elaborates EuropaBio’s position and policy recommendations to the European Commission across three key focus areas.
January 9, 2020

Inter-association letter to the European Commission and Member States

November 30, 2019

EuropaBio position on Germline Genome Editing

EuropaBio and its members strongly believe that genome editing will enable the development of many solutions to the grand challenges facing both people and planet.
June 25, 2019

Achieving the Potential of Genome Editing: the Perspective of the European Biotech Industry

EuropaBio, the voice of the biotech industry, has developed this paper to bring the latest views from the developers and users of genome editing tools and applications.
May 9, 2019

Open Letter to Member States on the EU Court Ruling on Mutagenesis

Open Letter to Member States on the EU Court Ruling on Mutagenesis.
April 20, 2019

Joint Statement on Horizon Europe

Health industries welcome unprecedented progress leading to an adoption of Horizon Europe, its areas for missions and partnerships.
February 28, 2019

EuropaBio Advanced Therapy

EuropaBio invites EU decision-makers to engage with us and our healthcare biotech members who are leading the field in advanced therapies.
November 29, 2018

Statement: As EU court ruling risks blocking innovation, the European biotech industry calls for science-based political decision making on genome edited products

As EU court ruling risks blocking innovation, the European biotech industry calls for science-based political decision making on genome edited products.
Become a member